Meier Ullrich, Kiefer Michael, Sprung Christian
Department of Neurosurgery, Unfallkrankenhaus Berlin, Berlin, Germany.
Surg Neurol. 2004 Feb;61(2):119-27; discussion 127-8. doi: 10.1016/j.surneu.2003.05.003.
Especially in patients with normal pressure hydrocephalus (NPH), conventional differential-pressure valves are known to create nonphysiological negative intraventricular pressure values (IVP) when the patient moves into the upright position, with the consequence of numerous, sometimes severe, complications. The recently presented gravitational devices promise improvement, primarily in respect to this disadvantage.
In a prospective multicenter study the new Miethke dual- switch valve (DSV) has been implanted in 128 patients with NPH. The patients have been assessed before operation, at discharge, and re-evaluated 6 to 9 months after surgery. The technical principle of the new device is presented.
The clinical follow-up showed excellent results in 63% of the patients, satisfactory results in 16%, and a bad outcome in 21% of the cases. The infection rate was 5%; the rate of mechanical complications including overdrainage and dislocations has been in total 9%, and underdrainage was suspected in 7 cases. The outcome correlated with the preoperative severity of NPH. Despite the clinical outcome, the computed tomography scans showed only minimal or no reduction of the ventricular size in the majority of cases. We found a valve-related rate of overdrainage of 2.5%, which is clearly lower than results of comparable series in the literature.
The clinical course of patients suffering from NPH is mainly influenced by the stage of the disease, the time of beginning of the therapy, and the gravitational function of the implanted device. Based on our clinical experiences with the Miethke dual-switch valve (MD-SV), we underscore the advantages of this valve for the treatment of hydrocephalus, especially for patients with NPH.
尤其是在正常压力脑积水(NPH)患者中,已知传统的压差阀在患者直立时会产生非生理性的脑室内负压值(IVP),从而导致许多有时甚至是严重的并发症。最近推出的重力装置有望改善这一主要缺点。
在一项前瞻性多中心研究中,128例NPH患者植入了新型米特克双开关阀(DSV)。在手术前、出院时对患者进行评估,并在术后6至9个月进行重新评估。介绍了新装置的技术原理。
临床随访显示,63%的患者效果极佳,16%的患者效果满意,21%的患者效果不佳。感染率为5%;包括引流过度和脱位在内的机械并发症发生率总计为9%,7例疑似引流不足。结果与术前NPH的严重程度相关。尽管有临床结果,但大多数病例的计算机断层扫描显示脑室大小仅略有减小或没有减小。我们发现与阀门相关的引流过度率为2.5%,明显低于文献中类似系列的结果。
NPH患者的临床病程主要受疾病阶段、治疗开始时间以及植入装置的重力功能影响。基于我们使用米特克双开关阀(MD-SV)的临床经验,我们强调该阀门在治疗脑积水方面的优势,尤其是对NPH患者。